when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Sanofi ($SNY) · news · pharmadog

← back to Sanofi

News mentioning $SNY

222 stories

Jun 12, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Jun 12, 26STAT+: Pharmalittle: We’re reading about a discontinued cancer drug, a Novo security breach, and morestat

Jun 11, 26STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and morestat

Jun 10, 26Sanofi stops immune drug trial in latest research setbackbiopharma dive

Jun 10, 26STAT+: Hope for Kendall Square’s lab marketstat

Jun 10, 26Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studyendpoints

May 15, 26STAT+: FDA leadership shakeup widens following Makary’s departurestat

May 11, 26STAT+: Colombia wins a key court ruling over a compulsory license issued for an HIV medicinestat

May 11, 26STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and morestat

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Trump reportedly plans to fire FDA Commissioner Makarystat

May 8, 26STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drugstat

May 8, 26STAT+: Up and down the ladder: The latest comings and goingsstat

May 8, 26STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and morestat

May 7, 26Key takeaways from WHO briefing on hantavirus cruise ship outbreakstat

May 7, 26Science is becoming less disruptive. Is an aging workforce to blame?stat

May 7, 26Official leading CDC’s cruise ship program retiresstat

May 7, 26STAT+: More political interference at the FDA?stat

May 7, 26STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and morestat

May 6, 26Trump administration’s drug strategy is at odds with recent actions on funding, policystat

May 6, 26STAT+: Administration report on most favored nation drug pricing raises new details — and questionsstat

May 6, 26Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive

May 6, 26STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with reviewstat

May 4, 26UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesbiopharma dive

Apr 29, 26Teva nabs experimental Tourette drug in $700M Emalex buyoutbiopharma dive

Apr 27, 26STAT+: An insider reveals the real goals of prior authorizationstat

Apr 27, 26STAT+: Astellas retries XLMTM gene therapy after deathsstat

Apr 27, 26STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialstat

Apr 27, 26STAT+: Veradermics’ hair loss drug succeeds in late-stage trialstat

Apr 27, 26STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studystat

← prevpage 7 of 8next →